



Chart: Opioid Legislation Advanced to the House Floor

May 18, 2018

This chart describes each of the bills addressing the opioid crisis that have been advanced to the House floor as of May 18, 2018. The bills were advanced in three separate markup sessions in the House Energy & Commerce and Ways & Means Committees. The Energy & Commerce Committee [convened](#) first on Wednesday, May 9 and advanced 25 bills ([background memo](#); [details](#)), and then completed its work in a [second markup](#), advancing an additional 32 bills on Thursday, May 17 ([background memo](#); [details](#)). The Ways & Means Committee approved its own group of eight legislative measures at a [markup](#) on Wednesday, May 16 ([details](#)). These bills will presumably inform the creation of a larger opioids legislative package, which is expected to receive consideration on the House floor in early-to-mid June.

ENERGY & COMMERCE COMMITTEE

CONTROLLED SUBSTANCES ACT			
Bill	Summary	Sponsor	Status
H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act (Text)	Would support the development and dissemination of materials giving pharmacists greater understanding and ability to decline to fill controlled substances when they suspect the prescriptions are fraudulent, forged, or appear to be for abuse or diversion. Introduced 11/7/2017.	Rep. DeSaulnier (D-CA) and Rep. Carter (R-GA); 9 Cosponsors	Approved by voice vote.
H.R. 5041 – Safe Disposal of Unused Medication Act (Text)	Allows hospice workers to safely dispose of unused controlled substances in patients’ homes, helping to reduce the number at risk of diversion or misuse. Introduced 2/15/2018.	Rep. Walberg (R-MI) and Rep. Dingell (D-MI); 17 Cosponsors	Approved, as amended , by voice vote
H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act (Text)	Updates federal law to improve dispensing of implantable and injectable therapies – developed to make abuse, misuse, and diversion more difficult. Introduced 3/7/2018.	Rep. Costello (R-PA) and Rep. Nolan (D-MN); 4 Cosponsors	Approved by voice vote.
H.R. 5483, Special Registration for Telemedicine Clarification Act (Text)	Directs HHS to promulgate interim final regulations to implement an existing law which permits the Attorney General to issue a special registration to health care providers to prescribe controlled substances via telemedicine in legitimate emergency situations, such as a lack of access to an in-person specialist. Introduced 4/12/2018.	Rep. Carter (R-GA) and Rep. Bustos (D-IL); 9 Cosponsors	Approved by voice vote.

PUBLIC HEALTH SERVICE ACT			
Bill	Summary	Sponsor	Status
H.R. 449 – Synthetic Drug Awareness Act (Text)	Requires Surgeon General to report on synthetic drugs’ public health impact on youth ages 12-18. Introduced 1/11/2017.	Rep. Jeffries (D-NY) 43 Cosponsors	Approved by voice vote.
H.R. 4284 – Indexing Narcotics, Fentanyl, and Opioids (INFO) Act (Text)	Directs HHS to create a public and easily accessible electronic dashboard linking to all of the nationwide efforts to combat the opioid crisis. An amendment in the nature of a substitute will also create an Interagency SUD Coordinating Committee to review and coordinate opioid use disorder (OUD) and other SUD research, services, and prevention activities across all relevant Federal agencies, evaluate the effectiveness of these activities, and make specific recommendations for actions. Introduced 11/7/2017.	Rep. Latta (R-OH); 7 Cosponsors	Approved, as amended , by voice vote
H.R. 5002 – Advancing Cutting Edge (ACE) Research Act (Text)	Grants NIH flexible authority to research new, non-addictive pain medications. Introduced 2/13/2018.	Rep. Dingell (D-MI) and Rep. Upton (R-MI); 6 Cosponsors	Approved by voice vote.
H.R. 5009 – Jessie’s Law (Text)	Directs HHS to implement standards for display of opioid addiction in medical records. Introduced 3/17/2017.	Rep. Walberg (R-MI) 14 Cosponsors	Approved, as amended , by voice vote
H.R. 5102 – Substance Use Disorder Workforce Loan Repayment Act (Text)	Creates a program to offer student loan repayment of up to \$250,000 for a wide range of health professionals who agree to work as a SUD treatment professional in areas most in need of their services. Introduced 2/27/2018.	Rep. Clark (D-MA), Rep. Rogers (R-KY); 20 cosponsors	Approved by voice vote.
H.R. 5176 – Preventing Overdoses While in Emergency Rooms Act (Text)	Provides resources for hospitals to develop protocols on discharging patients who have presented with an opioid overdose, addressing the provision of naloxone upon discharge, connection with peer-support specialists, and the referral to treatment and other services that best fit the patient’s needs. Introduced 3/6/2018.	Rep. McKinley (R-WV) and Rep. Doyle (D-PA); 5 Cosponsors	Approved by voice vote.
H.R. 5197 – Alternatives to Opioids (ALTO) in the Emergency Department Act (Text)	Establishes a demonstration program to test alternative pain management protocols to limit to use of opioids in hospital emergency departments. Introduced 3/7/2018.	Rep. Pascrell (D-NJ) and Rep. McKinley (R-WV); 8 Cosponsors	Approved, as amended , by voice vote
H.R. 5261 – Treatment, Education, and Community Help (TEACH) to Combat Addiction Act (Text)	Authorizes HHS to designate and support Centers of Excellence and institutions of learning that champion SUD treatment and pain management education to improve how health professionals are taught about both SUD and pain. Introduced 3/13/2018.	Rep. Johnson (R-OH) and Rep. Tonko (D-NY); 3 Cosponsors	Approved by voice vote.

H.R. 5272 – Reinforcing Evidence-Based Standards Under Law in Treating Substance Abuse (RESULTS) Act (Text)	Requires entities applying for federal mental health or SUD funding to submit materials demonstrating that the proposed programs or activities are evidence-based. Introduced 3/14/2018.	Rep. Stivers (R-OH) and Rep. Engel (D-NY); 9 Cosponsors	Approved by voice vote.
H.R. 5327, Comprehensive Opioid Recovery Centers Act (Text)	Establishes Comprehensive Opioid Recovery Centers (CORCs) to serve as models for comprehensive treatment and recovery, utilizing the full range of FDA-approved medications and evidence-based treatments. Introduced 3/19/2018.	Rep. Guthrie (R-KY) and Rep. Green (D-TX); 3 Cosponsors	Approved, as amended , by voice vote.
H.R. 5353, Eliminating Opioid-Related Infectious Diseases Act (Text)	Authorizes CDC to undertake an injection drug use-associated infection elimination initiative and work with states to improve education, surveillance, and treatment of infections associated with injection drug-use. Introduced 3/20/2018.	Rep. Lance (R-NJ); Rep. Kennedy (D-MA); 9 Cosponsors	Approved by voice vote.
H.R. 4684, Ensuring Access to Quality Sober Living Act (Text)	Authorizes SAMHSA to develop, publish, and disseminate best practices for operating recovery housing that promotes a safe environment and sustained recovery from SUD. Introduced 12/22/2017.	Rep. Chu (D-CA), Rep. Walters (R-CA); 15 Cosponsors	Approved by voice vote.
H.R. 5329, Poison Center Network Enhancement Act (Text)	Reauthorizes the national network of Poison Control Centers that serve as the primary resource for poisoning information. These centers reduce ER visits and report year over year increases in all analgesic exposures, including opioids and sedatives. Introduced 3/19/2018.	Rep. Brooks (R-IN) and Rep. Engel (D-NY); 5 Cosponsors	Approved, as amended , by voice vote.
H.R. 5580, STOP Fentanyl Deaths Act (Text)	Authorizes grants to federal, state, and local agencies for the establishment or operation of public health laboratories to detect fentanyl, its analogs, and other synthetic opioids. Introduced 4/23/18.	Rep. Kuster (D-NH); 2 Cosponsors	Approved by voice vote.
H.R. 5587, Peer Support Communities of Recovery Act (Text)	Enhances CARA’s Building Communities of Recovery Program and authorizes HHS to award grants to peer support specialist organizations for the development and expansion of recovery services. Introduced 4/23/2018.	Rep. Lujan (D-NM) and Rep. Johnson (R-OH).	Approved, as amended , by voice vote.
HR 5795 – Overdose Prevention and Patient Safety Act (Text)	Would align the use of SUD treatment records with HIPAA for the purposes of treatment, payment, and healthcare operations between covered entities. Would also enhance the penalties in the event of a disclosure of SUD treatment records, add breach notification requirements, and provide strong discrimination prohibitions to protect people seeking and receiving SUD treatment. Introduced 5/15/2018.	Rep. Mullin (R-OK) and Rep. Blumenauer (D-OR); 9 Cosponsors	Approved, as amended, by a vote of 35-17.

H.R. 5812, Creating Opportunities that Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies Act (CONNECTIONS) Act (Text)	Authorizes the CDC to carry out certain controlled substances overdose prevention and surveillance activities to improve data collection, timeliness, and accuracy for providers and dispensers in state-run prescription drug monitoring programs (PDMPs). Introduced 5/15/18.	Rep. Griffin (R-VA) and Rep. Pallone (D-NJ); 1 Cosponsor	Approved by voice vote.
MEDICARE PART B			
Bill	Summary	Sponsor	Status
H.R. 3331, To incentivize adoption and use of certified electronic health record technology (Text)	Amends title XI of the Social Security Act to promote testing of incentive payments for behavioral health providers for adoption and use of certified electronic health record technology. Introduced 7/20/2017.	Rep. Jenkins (R-KS) and Rep. Matsui (D-CA); 11 Cosponsors	Approved, as amended , by voice vote
H.R. 5685, Medicare Opioid Safety Education Act (Text)	Directs CMS to compile education resources for beneficiaries regarding opioid use, pain management, and alternative pain management treatments, and include these resources in the “Medicare and You” handbook. Introduced 5/7/2018.	Rep. Faso (R-NY) and Rep. Welch (D-VT); 3 Cosponsors	Approved by voice vote.
H.R. 5590, Opioid Addiction Action Plan Act (Text)	Establishes an Action Plan, including studies, reports to Congress authored by HHS, and meetings with stakeholders, for the purpose of addressing the opioid crisis. Introduced 4/24/2018.	Rep. Kinzinger (R-IL) and Rep. Clarke (D-NY); 3 Cosponsors	Approved, as amended , by voice.
H.R. 5603, Access to Telehealth Services for Opioid Use Disorder (Text)	Instructs CMS to evaluate the utilization of telehealth services in treating opioid use disorder. Introduced 4/24/2018.	Rep. Matsui (D-CA), Rep. Cardenas (D-CA), and Rep. Johnson (R-OH).	Approved, as amended , by voice.
H.R. 5605, Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Text)	Creates a demonstration project for an Alternative Payment Model (APM) for treating substance use disorder, including the development of measures to evaluate the quality and outcomes of treatment. Introduced 4/24/2018.	Rep. Ruiz (D-CA)	Approved, as amended , by voice.
H.R. 5798, Opioid Screening and Chronic Pain Management Alternatives for Seniors Act (Text)	Adds a review of current opioid prescriptions and, as appropriate, a screening for opioid use disorder as part of the Welcome to Medicare initial examination. Introduced 5/15/2018.	Rep. Bucshon (R-IN) and Rep. Dingell (D-MI); 1 Cosponsor	Approved by voice vote.
H.R. 5804, Post-Surgical Injections as an Opioid Alternative Act (Text)	Seeks to incentivize post-surgical injections as a pain treatment alternative to opioids by reversing a reimbursement cut for these treatments in the Ambulatory Service Center setting, as well as collect data on a subset of codes related to these treatments. Introduced 5/15/2018.	Rep. Shimkus (R-IL), Rep. Roskam (R-IL), and Rep. Krishnamoorthi (D-IL)	Approved by a vote of 36-14.
H.R. 5809, Postoperative Opioid Prevention Act of 2018 (Text)	Creates a temporary pass through payment to encourage the development of non-opioid drugs for post-surgical pain management in Medicare. Introduced 5/15/2018.	Rep. Peters (D-CA) and Rep. Bucshon (R-IN)	Approved by a vote of 34-17.

MEDICARE PART D			
Bill	Summary	Sponsor	Status
H.R. 3528, Every Prescription Conveyed Securely Act (Text)	Requires e-prescribing, with exceptions, for coverage of prescribed controlled substances under the Medicare Part D program. Introduced 7/28/2017.	Rep. Clark (D-MA) and Rep. Mullin (R-OK); 41 Cosponsors	Approved, as amended , by voice vote
H.R. 4841, Standardizing Electronic Prior Authorization for Safe Prescribing Act (Text)	Seeks to standardize electronic prior authorization for prescription drugs under Medicare Part D. Introduced 1/18/2018.	Rep. Schweikert (R-AZ); 17 Cosponsors	Approved, as amended , by voice vote
H.R. 5675, Mandatory Lock-In (Text)	Builds off of work done in the Comprehensive Addiction Recovery Act (CARA) to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries. Introduced 5/3/2018.	Rep. Bilirakis (R-FL), Rep. Lujan (D-NM); 2 Cosponsors	Approved by voice vote.
H.R. 5582 Abuse Deterrent Access Act (Text)	Directs CMS to evaluate the use of abuse-deterrent opioids in Medicare plans. Introduced 4/23/2018.	Rep. Carter (R-GA) and Rep. Loeb sack (D-IA); 2 Cosponsors	Approved, as amended , by voice vote
H.R. 5684, Protecting Seniors from Opioid Abuse Act (Text)	Adds beneficiaries at-risk for prescription drug abuse to the list of targeted beneficiaries to be eligible for MTM under Part D. Introduced 5/7/2018.	Rep. Kelly (R-PA) and Rep. Thompson (D-CA); 2 Cosponsors	Approved by voice vote.
H.R. 5686, Medicare Clear Health Options in Care for Enrollees (CHOICE) Act (Text)	Would require prescription drug plans under Medicare Part D to include information on the adverse effects of opioid overutilization and coverage of non-pharmacological therapies and non-opioid medications or devices used to treat pain. Introduced 5/7/2018.	Rep. Paulsen (R-MN) and Rep. Lamb (D-PA); 2 Cosponsors	Approved by voice vote.
H.R. 5715, Strengthening Partnerships to Prevent Opioid Abuse Act (Text)	Would help to facilitate communication between MA organizations, Part D plan sponsors, and CMS relating to substantiated fraud, waste, and abuse investigations. Introduced 5/9/2018.	Rep. Renacci (R-OH) and Rep. Sewell (D-AL); 4 Cosponsors	Approved, as amended , by voice.
H.R. 5716, Commit to Opioid Medical Prescriber Accountability and Safety for Seniors (COMPASS) Act (Text)	Would require CMS to establish a prescriber threshold based on specialty and geographic area, which could designate a prescriber as an outlier opioid prescriber. CMS would then be responsible for notifying prescribers identified as outliers of their status. Introduced 5/9/2018.	Rep. Roskam (R-IL) and Rep. Larson (D-CT); 2 Cosponsors	Approved by voice vote.
H.R. 5796, Responsible Education Achieves Care and Healthy Outcomes for Users' Treatment (REACH OUT) Act of 2018 (Text)	Directs CMS to work with Quality Improvement Organizations to engage in outreach with prescribers identified as clinical outliers to share best practices. Introduced 5/15/2018.	Rep. Fitzpatrick (R-PA) and Rep. Curbelo (R-FL); 2 Cosponsors	Approved by voice vote.

MEDICAID			
Bill	Summary	Sponsor	Status
H.R. 1925, At-Risk Youth Medicaid Protection Act of 2017 (Text)	Prohibits state Medicaid programs from terminating a juvenile's medical assistance eligibility because the juvenile is incarcerated. A state may suspend coverage while the juvenile is an inmate but must restore coverage upon release without requiring a new application unless the individual no longer meets the eligibility requirements for medical assistance. Introduced 4/5/2017.	Rep. Cardenas (D-CA) and Rep. Griffith (R-VA)	Approved by voice vote.
H.R. 3192, CHIP Mental Health Parity Act (Text)	Requires all Children's Health Insurance Program (CHIP) plans to cover treatment of mental illness and substance use disorders. Introduced 7/12/2017.	Rep. Kennedy III (D-MA); 19 Cosponsors	Approved, as amended , by voice.
H.R. 4005, Medicaid Reentry Act (Text)	Allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release. The bipartisan amendment requires the Secretary to convene a stakeholder group that will produce a report of best practices for states to consider in health care related transitions for inmates of public institutions. Introduced 10/10/2017.	Rep. Tonko (D-NY) and Rep. Turner (R-OH)	Approved, as amended , by voice.
H.R. 4998, Health Insurance for Former Foster Youth Act (Text)	Currently, foster youth with Medicaid coverage before they turn 18 may stay in Medicaid until the age of 26, unless they move out of their state. The bill allows for continued coverage even if they move to another state. The bipartisan amendment would revise the underlying policy and also direct CMS to publish guidance on how states can remove barriers, track coverage status, and conduct outreach to this population. Introduced 2/13/2018.	Rep. Bass (D-CA); 5 Cosponsors	Approved, as amended , by voice.
H.R. 5477, Rural Development of Opioid Capacity Services Act (Text)	Requires CMS to carry out a demonstration project to provide an enhanced Federal matching rate for state Medicaid expenditures related to the expansion of substance-use treatment and recovery services and provider capacity. Introduced 4/11/2018.	Rep. O'Halleran (D-AZ) and Rep. Blackburn (R-TN)	Approved, as amended , by voice.
H.R. 5583, Requiring Medicaid Programs to Report on All Core Behavioral Health Measures (Text)	Requires state Medicaid programs to report on the 11 behavioral health measures that are included in CMS's 2018 Core Set of Adult Health Care Quality Measures for Medicaid. Introduced 4/23/2018.	Rep. Clarke (D-NY)	Approved by voice vote.

H.R. 5789, To amend title XIX of the Social Security Act to provide for Medicaid coverage protections for pregnant and postpartum women while receiving inpatient treatment for a substance use disorder (Text)	Improves access to inpatient treatment services for women with substance use disorder who are pregnant or who are suffering from postpartum depression. Introduced 5/15/2018.	Rep. Foster (D-IL) and Rep. Guthrie (R-KY)	Approved, as amended , by voice.
H.R. 5797, IMD CARE Act (Text)	Allows state Medicaid programs from FY2019 through FY2023 to remove the Institutions for Mental Diseases (IMD) exclusion for Medicaid beneficiaries aged 21-64 with a opioid use disorder. Improves the continuum of care by removing a barrier to care under current law, so Medicaid would pay for up to 30 total days of care in an IMD during a 12-month period and eligible individuals can get the care they need. Introduced 5/15/2018.	Rep. Walters (R-CA); 3 Cosponsors	Approved, as amended , by voice.
H.R. 5799, Medicaid DRUG Improvement Act (Text)	Builds on current state Medicaid drug utilization review activities to help combat the opioid crisis. State Medicaid programs will be required to have safety edits in place for opioid refills, monitor concurrent prescribing of opioids and certain other drugs, and monitor antipsychotic prescribing for children. Introduced 5/15/2018.	Rep. Blackburn (R-TN); 2 Cosponsors	Approved, as amended , by voice.
H.R. 5800, Medicaid IMD ADDITIONAL INFO Act (Text)	Directs MACPAC to conduct a study on institutions for mental disease that receive Medicaid reimbursement. The study shall report on the requirements and standards that state Medicaid programs have in place for IMDs. MACPAC, considering input from stakeholders, shall summarize the findings and make recommendations on best practices and data collection. The report is due no later than January 2020. Introduced 5/15/2018.	Rep. Upton (R-MI) and Rep. Walters (R-CA)	Approved by voice vote.
H.R. 5801, Medicaid PARTNERSHIP Act (Text)	Requires the Medicaid program in each state to integrate prescription drug monitoring act (PDMP) usage into a Medicaid provider's clinical workflow and require such providers to check the PDMP before prescribing a Schedule II controlled substance. Establishes standard criteria that a PDMP must meet to be counted as a qualified PDMP and requires state Medicaid programs to report to CMS on several PDMP issues. Introduced 5/15/2018.	Rep. Griffith (R-VA) and Rep. Fitzpatrick (R-PA)	Approved, as amended , by voice.

H.R. 5808, Medicaid Pharmaceutical Home Act of 2018 (Text)	Requires all state Medicaid programs to have a beneficiary assignment program that identifies Medicaid beneficiaries at-risk for substance use disorder and assigns them to a pharmaceutical home program. The pharmaceutical home program must set reasonable limits on the number of prescribers and dispensers that beneficiaries may utilize. Introduced 5/15/2018.	Rep. Bilirakis (R-FL); 2 Cosponsors	Approved by voice vote.
H.R. 5810, Medicaid Health HOME Act (Text)	Improves the state option for Medicaid health homes under current law that improve the coordination of, and access to care for Medicaid beneficiaries with substance use disorder. The bill extends the enhanced matching rate for qualified activities from eight quarters to 10 quarters. Introduced 5/15/2018.	Rep. Lance (RNJ) and Rep. Welch (D-VT) and Rep. Rothfus (R-PA)	Approved, as amended , by voice.
FEDERAL FOOD, DRUG, AND COSMETIC ACT			
Bill	Summary	Sponsor	Status
H.R. 5473, Better Pain Management through Better Data Act (Text)	Directs the FDA to establish clear data collection methods for opioid-sparing labeling claims for products that may replace, delay, or reduce the use of opioid analgesics. Introduced 4/11/2018.	Rep. Comstock (R-VA) and Rep. Lujan (D-NM); 2 Cosponsors	Approved by voice vote.
H.R. 5687, Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act (Text)	Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. Facilitates utilization of packaging to reduce opioid overprescribing. Requires GAO to study safe disposal of unused opioids and other medications. Introduced 5/7/2018.	Rep. Hudson (R-NC) and Rep. Butterfield (D-NC); 1 Cosponsor	Approved by voice vote.
H.R. 5228, Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now (SCREEN) Act (Text)	Provides FDA with stronger recall and seizure authority, among other things, to disrupt the entry of counterfeit and illicit drugs through IMFs. This bill was not considered during the prior legislative hearings. Introduced 3/8/2018.	Rep. Pallone (D-NJ)	Approved, as amended (here and here), by voice vote.
H.R. 5752, Stop Illicit Drug Importation Act of 2018 (Text)	Streamlines and enhances FDA's tools to intercept illegal products including illicit or unapproved drugs entering the U.S through International Mail Facilities (IMFs). Introduced 5/10/2018.	Rep. Blackburn (R-TN)	Approved, as amended , by voice.
H.R. 5806, 21st Century Tools for Pain and Addiction Treatments (Text)	Directs the FDA to issue or update existing guidance on ways that the accelerated approval program and breakthrough therapy pathway can be used to bring novel non-addictive treatments for pain and addiction to patients. Introduced 5/15/2018.	Rep. Burgess (R-TX), Rep. Bucshon (R-IN), and Rep. Griffith (R-VA)	Approved by a vote of 31-23.

H.R. 5811, To amend the Federal Food, Drug, and Cosmetic Act with respect to post-approval study requirements for certain controlled substances, and for other purposes (Text)	enhance FDA’s authorities and enforcement tools to ensure timely post-marketing studies for chronically administered opioids. Currently, there is limited data on the long-term efficacy of opioids, their increased addictive tendencies over time, and their overall place in the treatment of pain. Introduced 5/15/2018.	Rep. McNerney (D-CA) and Rep. Griffith (R-VA)	Approved, as amended , by voice. Amendment adopted by vote of 31-22.
--	--	---	--

WAYS & MEANS COMMITTEE

WAYS & MEANS COMMITTEE LEGISLATION			
Bill	Summary	Sponsor	Status
H.R. 5774 – Combatting Opioid Abuse for Care in Hospitals (COACH) Act (Text)	Requires the Department of Health and Human Services (HHS) to develop Medicare guidance on pain management and opioid use disorder prevention for hospitals; provide for opioid quality measures development; and provide for a technical expert panel (TEP) on reducing surgical setting opioid use and data collection on perioperative opioid use, among other provisions. A description of the manager’s amendment is available here . Introduced 5/11/2018.	Rep. Curbelo (R-FL); 3 Cosponsors	Approved, as amended , by voice vote.
H.R. 5775 – Providing Reliable Options for Patients and Educational Resources (PROPER) Act (Text)	Requires Medicare Advantage (MA) plans and part D prescription drug plans (PDPs) to include information on the risks associated with opioids; coverage of certain nonopioid treatments used to treat pain; and on the safe disposal of prescription drugs, and for other purposes. A description of the manager’s amendment is available here . Introduced 5/11/2018.	Rep. Paulsen (R-MN); 3 Cosponsors	Approved, as amended , by voice-vote.
H.R. 5776 – Medicare and Opioid Safe Treatment (MOST) Act (Text)	Stipulates Medicare coverage of certain services furnished by opioid treatment programs; reviews and adjustment payments under the Medicare hospital outpatient prospective payment system (OPPS) to avoid financial incentives to use opioids instead of non-opioid alternative treatments; expands Medicare access to addiction treatment in federally-qualified health centers (FQHCs) and Rural Health Clinics (RHCs); studies the availability of MA supplemental benefits designed to treat or prevent substance use disorders (SUDs); includes provisions to enhance access to clinical psychologist service via models led by the Center for Medicare and Medicaid Innovation (CMMI), along with a	Rep. Richard Neal (D-MA); 3 Cosponsors	Approved, as amended , by voice vote.

	Government Accountability Office (GAO) study and report on Medicare mental and behavioral health services; and directs HHS to conduct a report with recommendations on whether and how payment to Medicare Part A and B providers/suppliers related to the use of multi-disciplinary, evidence-based non-opioid treatments for acute and chronic pain management should be revised. A description of the manager's amendment is available here . Introduced 5/11/2018.		
H.R. 5773 – Preventing Addiction for Susceptible Seniors (PASS) Act (Text)	Requires Medicare PDP sponsors to establish drug management programs for at-risk beneficiaries (“lock-in” programs); stipulates electronic prior authorization for covered Part D drugs; delineates program integrity measures for MA and Part D plans, including via sharing information between HHS and MA and Part D plans via a secure Internet website portal (with a contractual requirement to communicate plan corrective actions against opioid over-prescribers, among other requirements); stipulates expanded eligibility for Part D medication therapy management (MTM) programs to include at-risk beneficiaries for prescription drug abuse; and calls for Medicare notifications to outlier prescribers of opioids. A description of the manager's amendment is available here . Introduced 5/11/ 2018.	Rep. Roskam (R-IL); 3 Cosponsors	Approved, as amended , by voice vote.
H.R. 5676 – Stop Excessive Narcotics in our Retirement (SENIOR) Communities Protection Act (Text)	Authorizes the suspension of payments by Medicare prescription drug plans and MA-PD plans pending investigations of credible allegations of fraud by pharmacies. A description of the manager's amendment is available here . Introduced 5/3/2018.	Rep. MacArthur (R-NJ); 5 Cosponsors	Approved, as amended , by voice vote.
H.R. 5788 – Securing the International Mail Against Opioids Act of 2018 (Text)	Provides for the processing by U.S. Customs and Border Protection of certain international mail shipments and requires the provision of advance electronic information on international mail shipments of mail, among other provisions. A description of the manager's amendment is available here . Introduced 5/15/2018.	Rep. Bishop (R-MD); 3 Cosponsors	Approved, as amended , by voice vote.